NEW YORK, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, November 6, 2014 at 8:00 a.m. ET to discuss results for the third quarter of 2014 and provide an update on the business.
In order to participate in the conference call, please call 1-(888) 396-2320 (U.S.), 1-(774) 264-7560 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
Keryx will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's lead product, Ferric Citrate, was approved by the U.S. Food and Drug Administration on September 5, 2014.
For additional company information, including full prescribing information for Ferric Citrate, please visit www.keryx.com.
CONTACT: KERYX CONTACT: Amy Sullivan Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail: email@example.com
Source:Keryx Biopharmaceuticals, Inc.